Agilent Completes Stratagene Buy, Improves Q3 Financial Forecast Despite Revenue Decline | GenomeWeb
Agilent Technologies last week completed its acquisition of Stratagene for $10.94 a share, or $246 million, gaining access to the firm’s array-related software and reagent kits as well as growing its headcount by 450 and gaining Stratagene’s operations in Texas, California, Japan, and The Netherlands.
 
Separately, Agilent said that it expects third-quarter revenue to decline between 2 percent and 4.8 percent year over year, though it is a 1.5-percent improvement over earlier predictions.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.